Bleeding related adverse events associated with antiviral treatment in influenza patients: A disproportionality analysis using FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Sarker, Jyotirmoy [1 ]
Carkovic, Emir [2 ]
Lee, Todd A. [3 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1036
引用
收藏
页码：486 / 487
页数：2
相关论文
共 50 条
  • [21] A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
    Lin, Li
    Zheng, Xinlei
    Wu, Min
    Chen, Yan
    Nian, Qichun
    Lin, Yu
    Chen, Maohua
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [22] Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
    Li, Liangxia
    Xu, Qianqian
    Liu, Yarui
    Pang, Liangfang
    Cui, Zhou
    Lu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] PAIN AND ARTHRALGIA ADVERSE EVENTS ASSOCIATED WITH CRIZANLIZUMAB AND VOXELOTOR: DISPROPORTIONALITY ANALYSIS OF US FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS)
    Ologunowa, A.
    Caffrey, A. R.
    VALUE IN HEALTH, 2023, 26 (06) : S208 - S208
  • [24] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
  • [25] A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database
    Li, Jie
    Xie, Jun
    Han, Yi
    Zhang, Wei
    Wang, Yilei
    Jiang, Zhitao
    ENDOCRINE JOURNAL, 2025, 72 (03) : 273 - 283
  • [26] A disproportionality analysis of FDA adverse event reporting system events for misoprostol
    Yang, Li
    Xu, Wenting
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [27] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [28] A disproportionality analysis of real-world events from the FDA Adverse Event Reporting System (FAERS) for Atezolizumab
    Li, Zhuoyang
    Zhu, Ning
    Liu, Yuwei
    Yu, Yan
    Wang, Tianhong
    Zou, Congcong
    Wang, Siman
    Ou, Xiaofeng
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [29] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
  • [30] Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
    Du, Yikuan
    Zhang, Mengting
    Chen, Mianhai
    Hu, Mianda
    Zeng, Wenqi
    Cai, Xiaolin
    Zhang, Weichui
    Zhu, Jinfeng
    Zhong, Mingjun
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2025,
12345